A plasmapheresis machine is a device that collects small volumes of blood at a time using plasmapheresis. Plasmapheresis is the separation of blood into plasma and cells, followed by the return of the cells to circulation. It is done precisely to eliminate antibodies in the treatment of autoimmune diseases. Pheresis, also known as apheresis, is a procedure in which blood is extracted from the body, filtered, and stored before being returned to it. It is feasible to separate platelets, red blood cells, white blood cells, and plasma. During the procedure, a machine is utilised to remove small volumes of blood at a time.
There are two ways to separate the components of blood:
Centrifugation spins the blood and divides it into sections based on density.
Filtration: Plasma is isolated from blood with the use of a filter. During plasma exchange, the device will reject unhealthy plasma and replace it with healthy plasma from a donor. To replace dangerous plasma, saline, albumin, or a combination of the two can be utilised.
With a CAGR of 3.65 %, the Latin America plasmapheresis machines market is expected to grow significantly by 2030, reaching a total value of 107.5 million USD. Increased demand for blood and blood components, as well as a rising rate of blood donations, are the main drivers of the Latin America apheresis market. Furthermore, during the projection period, the rising prevalence of leukaemia, acute disseminated encephalomyelitis, multiple sclerosis, autoimmune haemolytic anaemia, and newborn cardiac lupus will propel the market forward.
| Report Metric | Details |
|---|---|
| Base Year | 2021 |
| Study Period | 2020-2030 |
| Forecast Period | 2023-2031 |
| CAGR | 3.65% |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
The Latin America plasmapheresis machines market is predicted to develop significantly by 2030, with a CAGR of 3.65%, reaching a total value of 107.5 million USD. The key drivers of the Latin America apheresis market include increased demand for blood and blood components, as well as an increasing rate of blood donations. The increased prevalence of leukaemia, acute disseminated encephalomyelitis, multiple sclerosis, autoimmune haemolytic anaemia, and newborn cardiac lupus will also move the market forward over the forecast period.
With a significant CAGR rate over the projected period, Argentina is expected to top the Latin American market and become the fastest-growing regional market. The rising prevalence of blood-related ailments such as kidney disease, metabolic disease, cancer, and neurological disorders, as well as expanding healthcare infrastructure and high levels of patient awareness, are all contributing to the region's market expansion. Health spending accounted for more than 9.7% of Argentina's gross domestic product in 2018, up from 10.50% the year before. Argentina has the second-highest health spending in GDP among Latin American and Caribbean countries.
Brazil accounted for the majority of the plasmapheresis machine market share in South America. The increased incidence of leukaemia, sophisticated diagnosis technologies, a huge population, and the expanding presence of technologically advanced items in the country are all factors in this region. With about 49 million children under the age of 15, leukaemia is a frequent paediatric malignancy in the region. Brazil has a 54 per million incidence rate for children aged 0 to 14. During the projection period, the existence of skilled doctors and advanced medical facilities is expected to present many potential prospects.
The Latin America Plasmapheresis Machines Market region is divided into four categories: type, application, end-user, and geography.
Multicomponent Collection Systems (MCCS) are a type of improved plasma collection system that collects different components of human blood during donation. It's frequently mixed with plasma as well as other components like serum, RBCs, and leukocytes. Although some definitions define the multi-component collection as a technique that yields two distinct blood components, the vast majority of research papers written by scientists around the world define multicomponent apheresis as a procedure that yields two or more identical or distinct blood components. The same centrifugation processes used for collecting each component individually under diverse circumstances are routinely applied for these multicomponent collections.
Plasmapheresis is an extracorporeal therapy procedure that involves the removal, treatment, return, and exchange of blood plasma and its constituents from and into the circulatory system. An extracorporeal procedure is one that takes place outside of the body. The extracorporeal therapy segment is growing due to an increase in autoimmune disorders such as thrombotic thrombocytopenic purpura, Goodpasture's syndrome, lupus, Guillain-Barre syndrome, myasthenia gravis, and other chronic illnesses, as well as government reimbursement programmes in developed countries and rising demand for plasma-derived medicines.
The hospitals and clinics category is expected to obtain the largest market share due to the recent COVID-19 pandemic increase. Due to COVID-19 infection, the frequency of therapeutic plasma exchange surgeries has increased, as have plasma and blood component contributions. During the forecast period, hospitals with in-house transfusion facilities are expected to improve the most.
